Published in FDA Law Weekly, November 24th, 2005
The study was the largest of its kind, according to Lyndon Mansfield, MD, Cobalis' senior medical advisor, and successfully concludes one of the most important milestones towards gaining FDA approval to market PreHistin in the U.S. as an over the counter (OTC) medication for preseasonal treatment of allergy symptoms.
The study demonstrated strong clinical and statistical significance that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.